Many cancer treatments can lead to reduced levels of sex hormones, which in turn may cause vasomotor symptoms (VMS) such as hot flashes. These symptoms are associated with impaired quality of life, as well as suboptimal tolerability of and adherence to cancer treatment. Hormone therapy, performed by increasing estradiol or testosterone levels, is the gold standard for treatment of VMS. However, this approach is generally contraindicated in patients with hormone-sensitive cancers. Nonhormone agents with low to moderate efficacy in controlling VMS are available, but their use may be limited by side effects and tolerability. In this narrative review, the approach to VMS in cancer patients will be discussed. The evidence for various treatment options, including novel agents such as fezolinetant that target the hypothalamic thermoregulatory pathway, will be evaluated. Finally, special considerations in different patient populations based on cancer types (eg, breast, prostate) and age groups (eg, older adults) will be explored.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879400 | PMC |
| http://dx.doi.org/10.1093/oncolo/oyaf002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rationale and Design of the ILIAS ANOCA Clinical Trial: a blinded-arm controlled trial for routine ad-hoc coronary function testing.
Am Heart J
March 2025
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address:
Angina with non-obstructive coronary arteries (ANOCA) is a major cause of chronic coronary syndromes, affecting nearly half of patients with anginal symptoms who undergo invasive coronary angiography. ANOCA may lead to substantial symptom burden, increased risk of adverse cardiac events, increased healthcare utilization due to ongoing symptoms, repeat hospitalizations, and invasive testing. The pathophysiology of ANOCA often involves a variety of coronary disorders, such as coronary microvascular dysfunction, epicardial or microvascular vasospasm and endothelial dysfunction.
View Article and Find Full Text PDFVirtual reality for menopause symptom management: opportunities, challenges, and next steps.
Menopause
March 2025
Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Importance And Objective: Menopause is the natural cessation of ovarian function, typically occurring at a mean age of 52 years in the United States. Vasomotor symptoms (VMS; hot flashes and night sweats) affect over 75% of midlife women and typically last 7 to 9 years, with only 54% seeking medical attention. Although hormone therapy is the most effective treatment for VMS, <4% of women currently use it, primarily due to safety concerns.
View Article and Find Full Text PDFNeurophysiological correlates of subjective cognitive decline in perimenopausal and postmenopausal midlife women at risk for Alzheimer's disease.
Menopause
March 2025
Department of Radiology, Weill Cornell Medicine, New York, NY.
Objective: This study aimed to investigate neurophysiological correlates of subjective cognitive decline (SCD) among midlife women at risk for Alzheimer's disease (AD).
Methods: We examined 156 cognitively normal perimenopausal and postmenopausal women aged 40 to 65 years, with an AD family history and/or apolipoprotein E epsilon 4 genotype, who were not on menopause hormone therapy. Participants underwent neuropsychological testing, health and menopausal symptom questionnaires, and brain volumetric magnetic resonance imaging, arterial spin labeling-magnetic resonance (MR) measuring cerebral blood flow, and 31phosphorus magnetic resonance spectroscopy (31P-MRS) measuring mitochondria high-energy phosphates (adenosine triphosphate [ATP], phosphocreatine [PCr], inorganic phosphate [Pi]).
Association of dysautonomia with refractory ventricular tachyarrhythmia in patients requiring thoracoscopic surgical cardiac sympathetic denervation.
JTCVS Open
February 2025
Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Objective: Although cardiac sympathetic denervation (CSD) effectively manages refractory ventricular tachyarrhythmias (RVTs) in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia, the link between dysautonomia and RVT from broader etiologies is understudied. We hypothesized that dysautonomia is linked to RVT regardless of etiology in patients requiring CSD. We aimed to determine whether these patients have a high burden of dysautonomia symptoms using the Composite Autonomic Symptom Score-31 (COMPASS-31).
View Article and Find Full Text PDFMenopause part I: Vasomotor symptoms (I).
Taiwan J Obstet Gynecol
March 2025
Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan. Electronic address:
Menopause, an aged process due to loss of permanent ovarian function (mainly decreased production of estrogen) without another pathological or physiological cause becomes one of the most health issues in the world. Vasomotor symptoms (VMS) is a hallmark of menopause, occurring in up to 80 % of women experiencing and persisting for over seven years with significant negative impacts on physical, psychological, social, and overall wellbeing. Conventionally, menopause hormone therapy (MHT) is considered the most effective therapeutic opinion for many years based on the fact as "deficiency of estrogen"; however, the ratio of benefits and risk is highly debated and always in concern.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!